In this study, we reported a 59-year-old female patient with FGFR3–TACC3 (F17:T10) fusion, no smoking history, tumor located in the right lung with lymphatic, liver, and bone metastases, clinical stage T4N3M1, pathologically confirmed as PPLELC, Genetic analysis revealed FGFR3–TACC3 (F17:T10) fusion without EGFR, ALK and other conventional mutations. This evidence concerns the gene ALK and neoplasm.